Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients
|
|
- Cory Maxwell
- 6 years ago
- Views:
Transcription
1 European Review for Medical and Pharmacological Sciences Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients 2013; 17: L. MAHMOUDI 1, A.H. MOHAMMADPOUR 1, A. AHMADI 2, R. NIKNAM 3,4, M. MOJTAHEDZADEH 2,5 Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. 1 Department of Pharmacodynamics and Toxicology, Pharmaceutical Research Center and School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 2 General Intensive Care Unit of Sina Teaching Hospital affiliated to School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4 Gastroenterology and Hepatology Section, Fasa University of Medical Sciences, Fasa, Iran. 5 Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Abstract. BACKGROUND AND OBJECTIVES: Severe sepsis is a major problem as cause of high rates morbidity and mortality in intensive care units (ICU). Aminoglycosides are an important group of antimicrobials used for severe sepsis. However, aminoglycoside pharmacokinetics in ICU patients may be altered during sepsis, which can affect the drug concentrations. Therefore, this study was undertaken to examine the relationship between amikacin disposition kinetics after a 25 mg/kg loading dose and hemodynamic response to sepsis, as well as clinical parameters, in a population of critically ill patients. METHODS: In this work, 30 patients who were candidate to amikacin therapy following Gram negative sepsis were enrolled. The pharmacokinetic profile of amikacin by a non-compartmental model was calculated for each patient. RESULTS: Mean volume of distribution was 0.36 ± 0.07 L/kg and mean serum amikacin clearance was 3.88 ± 0.97 ml/min/kg. In the case of Vd, APACHE II score correlation was significant. In the case of amikacin clearance, two covariates including creatinine clearance and Sr Cr significant correlation was found. CONCLUSIONS: It appears necessary to use higher amikacin dosage ( 25 mg/kg) considering hemodynamic response of patients to sepsis. To achieve therapeutic drug concentration a close drug monitoring and a shift from the population mean toward a value more representative of the critically ill patient subpopulation is crucial. Key Words: Amikacin, Pharmacokinetics, Sepsis, Critically ill patients, Aminoglycosides. Introduction Treatment of infections in critically ill patients is a serious challenge for intensive care unit (ICU) physicians, because these infections are associated with high rates of mortality and morbidity 1. Up to 50% of all patients diagnosed with severe sepsis will die during their hospital admission 2. Selection of appropriate antibiotic is the mainstay of treatment, since an inappropriate initial choice may be responsible for higher therapeutic failure and higher mortality rates 3,4. Aminoglycosides are an important group of antimicrobial agents for severe sepsis and septic shock due to the desirable properties not exhibited by other classes of antibiotics 5. Amikacin is a highly potent aminoglycoside, extensively used in ICUs to treat patients with life-threatening Gram-negative infections, with an excellent therapeutic value 6. Amikacin has structural differences from the rest of aminoglycosides that makes it a more suitable option for the treatment of serious infections. Because of these structural differences, amikacin is not inactivated by common bacterial enzymes and a lower appearance of resistance has been observed with its use 7. Pharmacokinetic (PK)/pharmacodynamic (PD) relationship of amikacin, like other aminoglycosides, is concentration dependent and the ability to treat infections is strongly associated with a high peak serum concentration 8. Therefore, clinical estimates of amikacin dosage based on aver- Corresponding Author: Mojtaba Mojtahedzadeh, Pharm D, BCPS; mojtahed@sina.tums.ac.ir 285
2 L. Mahmoudi, A.H. Mohammadpour, A. Ahmadi, R. Niknam, M. Mojtahedzadeh Statistical Analysis Descriptive statistics were computed for all study variables. All data were entered to a database system. Correlation between groups was anage drug characteristics are inaccurate in critically ill patients, since aminoglycoside PK may be altered in ICU patients during sepsis, which can affect the drug concentrations 9. These PK alterations may lead to unpredictable and variable exposure to amikacin when administered to these patients at conventional doses. Thus, optimizing amikacin dosing regimen to enhance antibacterial activity and therapeutic response might need higher doses of aminoglycosides 10. Although the PK disposition of aminoglycosides has been studied before 7,11,12, limited PK data are available on higher dose amikacin in critically ill septic patients 10,13. Moreover, the interpretation of this data is complicated since usually patients admitted to ICUs are not a homogenous population, due to diverse underlying diseases and severities of the illness 14. Therefore, this study was undertaken in a population of critically ill patients to examine the relationship between the amikacin disposition kinetics after a 25 mg/kg loading dose and the hemodynamic response to sepsis, as well as clinical parameters. Methods Study Population In this study, 30 patients with a diagnosis of severe sepsis 15 hospitalized in a general ICU between March 2010 and March 2011 were recruited. The legally authorized representative of each eligible patient was informed about the objectives of study and a written consent was obtained. This study was approved by our Institutional Investigational Review Board for human and animal studies. Patients, who were candidate to receive amikacin following Gram-negative sepsis, were enrolled. Patients were excluded according to the following criteria: age under 18 or over 65 years, pregnancy, extensive burns ( 20% of body surface area), ascites, inadequate renal function (creatinine clearance < 60 ml/min), known cochleovestibular abnormalities, myasthenia gravis, and allergy to aminoglycosides, meningitis, endocarditis, immunodeficiency, and treatment with aminoglycosides in the previous 2 weeks. During the empiric antibiotic therapy, amikacin with a loading dose of 25 mg/kg (intravenously over 60 minutes) was co-administered with a β-lactam antibiotic or carbapenem. Drug Assays In each case, 5 ml of blood was collected by infusion set following establishment of good laboratory practices at 0, 0.25, 0.5, 1.5, 4.0, 8.0, 12.0, 18 and 24 hours after the start of i.v. infusion in a 5-ml plain tube (without anticoagulant). When a clot had completely formed (15 to 30 min), the sample was centrifuged at 4 C, and the serum was stored at 80 C until analysis. Serum concentrations of amikacin were quantified at the end of the study by means of fluorescence polarization immunoassay with the TDx analyzer (Abbott GmbH, Wiesbaden, Germany). According to the manufacturer, the limit of quantitation for this assay was 0.6 mg/l and the analytical precision was 3.18%, 2.62%, and 2.50% for low (5 mg/l), medium (15 mg/l), and high (30 mg/l) concentrations, respectively. Data Collection Whenever a blood sample was taken, all relevant demographic data (e.g. age, gender, total body weight (TBW), disease severity as characterized by the Acute Physiology and Chronic Health Evaluation (APACHE) II score 16, central vein pressure (CVP) were recorded. In addition several laboratory tests including complete blood count (CBC), serum creatinine (Sr Cr), blood urea nitrogen (BUN), liver function tests, and electrolytes were performed at inclusion and at 24 hours. Creatinine clearance (CrCl) was estimated with the Cockcroft and Gault equation by using TBW 17. Pharmacokinetic The pharmacokinetic profile of amikacin was analyzed by a non-compartmental model 18 and following pharmacokinetic variables were calculated for each patient. Total volume of distribution (Vd), total body clearance (Cl), elimination half-life (t 1/2 ), area under the curve (AUC) during the 24 hours, Peak (amikacin level measured 30 min after the completion of infusion) and trough (concentration 24 h after the start of infusion). Peak > 64 µg/ml was considered optimal concentration by expectance a mean Vd of 0.4 L/kg and the threshold of toxicity was determined by a trough > 5 µg/ml 10,
3 Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients alyzed by using the Pearson correlation test and comparison between two groups was analyzed by the use of one sample t-test. (SPSS software for windows, version 11.5; SPSS Inc., Chicago, IL, USA). p value less than 0.05 was considered significant. Results Characteristics of the Study Population The study population consisted of 30 critically ill patients with the diagnosis of severe sepsis in which amikacin treatment was indicated. Demographic and laboratory tests of the patients are shown in Table I. Pharmacokinetic Data The median amikacin dose was 1500 mg ( ) which was administered intravenously over 60 minutes. Main PK parameters for amikacin are presented in Table II. The mean value (± standard deviation) of amikacin plasma concentration-time profiles of patients are shown in Figure 1. The current value of Vd 19 and Cl 20 of amikacin observed in critically patients were 0.36 ± 0.07 L/kg and 3.88 ± 0.94 ml/ min/kg respectively, in comparison with a Vd of 0.25 L/kg and Cl of 1.37 ml/min/kg in non-critically ill patients, by using one sample t-test (p < 0.05). Therapeutic Drug Monitoring of Amikacin The peak serum concentrations were > 64 µg/ml in 75% of patients (Figure 2). No patient had trough concentration > 5 µg/ml (Figure 3). Table I. Characteristics of the study population. Characteristics Value Demographic data Age (years) ± 14.2 Total Body Weight (kg) ± 9.57 Male/ Female (%) 70/30 APACHE II score ± 5.54 Mean arterial pressure (mmhg) 78 ± 11 Central venous pressure (mmhg) 12 ± 4 ph 7.41 ± 0.06 PaCO 2 (mmhg) ± 7.18 HCO 3 (mmol/l) ± 3.82 Laboratory tests AST(U/L) ± ALT(U/L) ± Sr Cr(mg/dl) 0.82 ± 0.18 BUN(mg/dl) ± Cr Cl (ml/min/1.73 m 2 ) 69 ± 7.53 WBC (/µl) ± Hb (g/dl) 9.93 ± 1.48 Platelets (/µl) ± Na (meq/l) ± 4.32 K(meq/L) 3.40 ±.52 Albumin(mg/dl) 2.97 ± 0.47 Urine output (ml/24 h) ± Data are expressed as percentage or mean ± SD, Sr Cr: serum ceratinine, BUN: Blood Urea Nitrogen, APACHE: Acute Physiology and Chronic Health Evaluation, Cr Cl: creatinine clearance, Alb: serum albumin concentration. Relationship Between Amikacin Pharmacokinetic Values and Patients Variables Relationship between amikacin Vd and Cl and patient s age, TBW, APACHE II score, Cr Cl and Sr Cr, as determined by Pearson correlation test, is shown in Table III. The APACHE II score s correlation was significant with amikacin Vd (p < 0.05). In the case of amikacin Cl, two covari- Table II. Pharmacokinetic parameters of the studied population. Parameter Minimum Maximum Mean ± SD CV (%) AUC (mg hr/ml) ± AUMC ± MRT (hr) ± t 1/2 (hr) ± Cl (ml/min/kg) ± Vd (L/kg) ± Peak (µg/ml) ± Trough (µg/ml) ± AUC: area under the serum level-time curve, AUMC: area under the moment versus time curve, MRT: mean residence time, t 1/2 : elimination half-time, Cl: total body clearance, Vd: volume of distribution, CV: coefficient of variation 287
4 L. Mahmoudi, A.H. Mohammadpour, A. Ahmadi, R. Niknam, M. Mojtahedzadeh Concentrations mg/l Patients (%) Time (h) Figure 1. Mean concentration-time (± SD) profile of amikacin. Serum trough concentrations (µg/ml) Figure 3. Distribution of trough concentrations. Patients (%). Patients (%) Peak serum trough concentrations (µg/ml) Figure 2. Distribution of peak concentrations. Black bars, peak > 64 µg/ml; gray bars, peak < 64 µg/ml. Patients (%). ates including Cr Cl and Sr Cr significant correlation was found (p < 0.05). No significant correlations between other variables and amikacin Cl and Vd were found. Discussion As far as we know, limited studies have described higher dose amikacin in ICU septic patients 10,13. Our study shows the pharmacokinetic values of a 25 mg/kg loading dose of amikacin and the influence of patients variables on this higher dose in a population of severe septic patients. Table III. Relationship between amikacin PK values and patients variables. Variable Vd Cl t 1/2 C max Age 0.36 (0.122) 0.12 (0.424) 0.13 (0.596) (0.026) TBW (0.568) 0.40 (0.079) (0.004) (0.370) APACHE II 0.45 (0.044) 0.14 (0.567) 0.24 (0.309) (0.244) Cr Cl (0.279) 0.49 (0.027) (0.001) 0.12 (0.627) Sr Cr (0.932) (0.025) 0.45 (0.047) 0.63 (0.003) Data are expressed as Pearson Correlation: r2 (p value), Vd: volume of distribution, Cl: total body clearance, t 1/2 : elimination half-time, C max : peak concentration, TBW: total body weight, BUN: blood urea nitrogen, APACHE: Acute Physiology and Chronic Health Evaluation, Cr Cl: creatinine clearance, Sr Cr: serum creatinine. 288
5 Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients The present study demonstrated that a profound change in amikacin disposition kinetics happens in response to sepsis in critically ill patients. Therefore, a higher dose schedule of amikacin might be needed to achieve optimal serum concentrations. Critically ill patients normally are not a homogenous population, because there are varieties in the patient presentation, differences in underlying disease, levels of disease severity and organ function 14. Most dosing regimens applied in ICU patients are founded on clinical trials involving non-icu patients or healthy volunteers, based on the assumption that PK variables are similar between these two groups 21,22. However, several pathophysiological changes occurring in ICU patients with sepsis can affect drugs PK behavior 10. Hyperdynamic conditions, including an increased basal metabolic energy expenditure (BEE), cardiac output and oxygen consumption, frequently occur in the early phase of sepsis in response of body to infective insult 12. Moreover, dynamic changes in volume status and end organ dysfunction can lead to altered PK properties of many drugs 22. Various factors concerning the disease are correlated to aminoglycoside pharmacokinetics in the critically ill patients 23 who often display an increased Vd for aminoglycosides and this leads to a decreased peak serum concentration 6. In our investigation the mean Vd was 0.36 ± 0.07, significantly higher than the Vd of 0.25 L/kg in non-critically ill patients 19. This finding was consistent with most reported values in septic patients, confirmed that sepsis induced Vd change under similar conditions. Changes of Vd in critically ill patients were reported by Triginer et al 24. In this study, in a group of critically ill patients, Vd in the first phase of the research was 0.43 ± 0.12 L/kg. Lugo et al 12 evaluated amikacin disposition in 30 critically ill patients and reported that mean Vd of amikacin was 0.47 L/kg, a value significantly increased in comparison with healthy volunteers. Taccone et al 10 and Marik et al 25, using amikacin in ICU patients with severe Gram-negative infections, referred that the mean Vd of amikacin was 0.37 L/kg and 0.41 L/kg respectively. Different factors are responsible of changes in Vd in critically ill patients. Endotoxins from bacteria can lead to the production of numerous mediators affecting vascular endothelium and increased permeability 26. Edematous status may cause clinical failure of antimicrobial therapy via increasing Vd and lowering antimicrobial concentrations 27. Furthermore, capillary permeability, fluid therapy and total parenteral nutrition (TPN) may contribute in critically ill patients to expand the extracellular fluid and Vd and, as a result, a greater dilution of the aminoglycosides 28. Increased sickness severity, as measured by the APACHE II score, has been shown to be related to higher Vd for aminoglycosides 29. According to our findings, amikacin Vd was affected by patients APACHE II score. Data reported by Marik et al 29 and Lugo et al 30 as well as our data, support an association between sepsis severity, as estimated by the APACHE II score, and the expansion of the aminoglycoside Vd. According to our results, the amikacin Cl in septic patients was significantly higher than amikacin Cl in non-icu patients likewise to Tang et al 23 who found that the clearance of gentamicin was 1.5-fold higher in hyperdynamic septic patients. In the critically septic patients, physiopathologic changes determined by sepsis and associated stress, hemodynamic status and medical interventions determine a wide variability in aminoglycoside Cl. The body response to infection and injury lead to the increase of BEE, oxygen consumption, and higher cardiac output, blood flow and organ perfusion. In severe sepsis cardiac index is normal or even increased compared with that in the absence of organ dysfunction; renal artery blood flow is also increased resulting in the enhanced delivery and excretion of hydrophilic agents like aminoglycosides 31. Amikacin is primarily eliminated by glomerular filtration and, thus, modifications in renal function should directly affect the drug s clearance 32. In our results, there was a significant correlation between amikacin Cl and Cr Cl that was similar to other researches 12,33. The loading dose is directly proportional to the drug Vd 34, and an optimal regimen for aminoglycoside therapy would assure an adequate initial drug level, thus minimizing the opportunity for adaptive resistance 35. According to Jackson et al 35, the primary bactericidal phase is rapid and drug concentration dependent. During this initial phase, the killing rate is directly related to the initial drug concentration. 75% of our patients achieved the target peak concentration of > 64 µg/ml by using a 25 mg/kg dose of amikacin. But still 25% of them had a peak concentration below the target level and it shows the necessity of using even higher doses in these patients. 289
6 L. Mahmoudi, A.H. Mohammadpour, A. Ahmadi, R. Niknam, M. Mojtahedzadeh Nephrotoxicity of aminoglycosides has been associated with elevated trough concentrations 36. In our work, trough concentrations were well below 5 µg/ml for all patients. Optimizing aminoglycoside concentrations according to patient pharmacokinetic model is crucial to enhance efficacy while minimizing complications due to toxicity 5. Therefore, based on our findings, by using amikacin dose of 25 mg/kg, although most of patients reached optimal peak level, we couldn t achieve target peak concentration in a portion of our patients. Since amikacin is known to be a concentration-dependent antimicrobial drug, it shows that by individualizing dosage regimen, and probably using a dose of 25 mg/kg, we may enhance efficacy by optimizing peak concentration. Meanwhile, because of low trough levels in this regimen it could help reducing the risk of amikacin nephrotoxicity. Two major limitations exist in our investigation. First, a control group without sepsis was not included, because administration of a higher dose of a potentially toxic antibiotic to nonseptic patients was not ethical. Second, our study was limited to first 24 hours of amikacin administration. However, resolution of sepsis resulted in decline of Vd and Cl. In conclusion, our study have showed the importance of factors associated with physiologic response of patients due to sepsis, and their clinically relevant influence on the variability of pharmacokinetic profile of amikacin. Subtherapeutic levels of amikacin possibly due to the increase in Vd and Cl, represents a serious challenge for achieving target concentrations rapidly and efficiently, and thus control of the septic process. Therefore, it appears necessary to adjust amikacin dosage considering hemodynamic response of patients and a shift from the population mean toward a value more representative of the critically ill patient subpopulation. To maximize amikacin antibacterial effect, a close drug monitoring and dosing of amikacin at high doses ( 25 mg/kg) is probably required. This will help in defining more precisely optimal peak concentrations of amikacin that provide the greatest effectiveness with least toxicity. References 1) BRUN-BULSSON C. ICU-acquired infections and sepsis: more of a deadly duo. Intensive Care Med 2008; 34: ) ZENI F, F REEMAN B, NATANSON C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: ) KUMAR A, ROBERTS D, WOOD KE, LIGHT B, PARRILLO JE, SHARMA S, SUPPES R, FEINSTEIN D, ZANOTTI S, TAIBERG L, GURKA D, KUMAR A, CHEANG M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: ) LEIBOVICI L, SHRAGA I, DRUCKER M, KONIGSBERGER H, SAMRA Z, PITLIK SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: ) FAUVELLE F, PERRIN P, BELFAYOL L, BOUKARI M, CHERRIER P, B OSIO AM, TOD M, COULAUD JM, PETITJEAN O. Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics. Antimicrob Agent Chemother 1994; 38: ) VANHAEVERBEEK M. Pharmacokinetics of once-daily amikacin in elderly patients. Antimicrob Agent Chemother 1993; 31: ) LORTHOLARY O, TOD M, COHEN Y, P ETITJEAN O. Aminoglycosides. Med Clin North Am 1995; 79: ) OLSEN KM, RUDIS MI, REBUCK JA, HARA J, GELMONT D, MEHDIAN R, NELSON C, RUPP ME. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32: ) BUIJK SE, MOUTON JW, GYSSENS IC, VERBRUGH HA, BRUINING HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intens Care Med 2002; 28: ) TACCONE FS, LATERRE PF, SPAPEN H, DUGERNIER T, DE- LATTRE I, LAYEUX B, DE BACKER D, WITTEBOLE X, WALLEMACQ P, V INCENT JL, JACOBS F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53: ) BRESSOLLE F, GOUBY A, MARTINEZ JM, JOUBERT P, SAISSI G, GUILLAUD R, GOMENI R. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 1996; 40: ) LUGO G, CASTANEDA-HERNANDEZ G. Relation between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25: ) DELATTRE IK, MUSUAMBA FT, NYBERG J, TACCONE FS, LATERRE PF, VERBEECK RK, JACOBS F, WALLEMACQ PE. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 2010; 32: ) YAMAMURA S. Clinical application of artificial neural network (ANN) modeling to predict pharmacokinetic parameters of severely ill patients. Adv Drug Deliv Rev 2003; 55:
7 Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients 15) BONE RC, FISHER CJ JR, CLEMMER TP, SLOTMAN GJ, METZ CA, BALK RA. Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17: ) KNAUS WA, DRAPER EA, WAGNER DP, ZIMMERMAN JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: ) COCKCROFT DW, GAULT MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: ) NORWICH KH. Non compartmental models of whole-body clearance of tracers: A review. Ann Biomed Eng 1997; 25: ) TRIGINER C, IZQUIERDO I, FERNÁNDEZ R, TORRENT J, BENITO S, NET A, JANE F. Changes in gentamicin pharmacokinetic profile induced by mechanical ventilation. Eur J Clin Pharmacol 1991; 40: ) BAUER LA, EDWARDS WA, DELLINGER EP, SIMONOWITZ DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: ) MCKINDLEY DS, HANES S, BOUCHER BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18: ) POWER BM, FORBES AM, VAN HEERDEN PV, ILETT K. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: ) TANG GJ, TANG JJ, LIN BS, KONG CW, LEE TY. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43: ) TRIGINER C, IZQUIERDO I, FERNANDEZ R, RELLO J, TOR- RENT J, BENITO S, NET A. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16: ) MARIK PE, HAVLIK I, MONTEAGUDO FS, LIPMAN J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991; 27: ) BONE RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: ) HANSEN M, CHRISTRUP LL, JARLØV JO, KAMPMANN JP, BONDE J. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001; 45: ) TORMO C, ABAD FJ, RONCHERA-OMS C.L, PARRA V, JIMENEZ N.V. Critically-ill patients receiving total parentral nutrition show altered amikacin pharmacokinetics. Clin Nutr 1995; 14: ) MARIK PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intens Care 1993; 21: ) LUGO-GOYTIA G, CASTANEDA-HERNANDEZ G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000; 34: ) PEA F, V IALE P. The antimicrobial therapy puzzle: could pharmacokinetics-pharmacodynamics relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42: ) ZASKE DE, CIPOLLE RJ, ROTSCHAFER JC, KOHLS PR, STRATE RG. Individualizing amikacin regimens; accurate method to achieve therapeutic concentrations. Ther Drug Monit 1991; 13: ) FIRSOV AA, NASONOV VN. Correlation between aminoglycoside pharmacokinetic parameters and patient s factors: From statement to implication for individual dosage design. Eur J Drug Metab Pharmacokinet 1991; 3: ) WADA DR, DROVER DR, LEMMENS HJ. Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998; 35: ) JACKSON GG, LOLANS VT, DAIKOS GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: ) FISMAN DN, KAYE KM. Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am 2000; 14:
Introduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationAntimicrobial therapy in critical care
Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting
More information2. Albany College of Pharmacy and Health Sciences, Albany, NY, USA
AAC Accepted Manuscript Posted Online 17 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01032-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 Optimizing the Initial
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationPharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukaemia
Turkish Journal of Cancer Vol.31/ No. 3/2001 Pharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukaemia NADEEM IRFAN BUKHARI 1, SAMIA YOUSUF 2, MUHAMMAD JAMSHAID
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationAmikacin monotherapy for pan-resistant Pseudomonas aeruginosa sepsis
AAC Accepts, published online ahead of print on 7 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00441-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAdequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial
BRIEF REPORT Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial Rodger D. MacArthur, 1 Mark Miller, 2 Timothy Albertson, 3 Edward Panacek, 3
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationUpdate on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015
Update on Therapeutic Drug Monitoring - Aminoglycosides Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust What are common
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationPharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient
Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi
More informationONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS
ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give
More informationANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE
ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationOriginal Research Article
Study of Preterm Infants with Different Gestational Age: Modifying Amikacin Sulphate Dosage Regimen 1 1,2 Bindiya Chauhan, Sunil S Jalalpure Dr. Prabhakar Kore Basic Science Research Center, KLE Academy
More informationTaiwan Crit. Care Med.2009;10: %
2008 30% 2008 2008 2004 813 386 07-346-8339 E-mail srwann@vghks.gov.tw 66 30% 2008 1 2008 2008 Intensive Care Med (2008)34:17-60 67 2 3 C activated protein C 4 5,6 65% JAMA 1995;273(2):117-23 Circulation,
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationSepsis is the leading cause of morbidity and mortality in
J Vet Intern Med 200;18:728 733 Pharmacokinetics of Once-Daily Amikacin in Healthy Foals and Therapeutic Drug Monitoring in Hospitalized Equine Neonates Erica Paige Bucki, Steeve Giguère, Margo Macpherson,
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationLa sepsi Il ruolo dell antibiotico terapia
Congresso Nazionale AcEMC Fermo 11-12 Maggio 2017 La sepsi Il ruolo dell antibiotico terapia Michele Bartoletti Infectious Disease Unit - Sant Orsola Hospital, Bologna, Italy Disclosures: none Epidemiology
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationAntimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill
Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Arthur RH van Zanten, MD PhD Internist-intensivist Department of Intensive care Gelderse Vallei Hospital, Ede The Netherlands
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationWelcome! 10/26/2015 1
Welcome! Audio for this event is available via ReadyTalk Internet Streaming. No telephone line is required. Computer speakers or headphones are necessary to listen to streaming audio. Limited dial-in lines
More informationICU Volume 14 - Issue 4 - Winter 2014/ Matrix
ICU Volume 14 - Issue 4 - Winter 2014/2015 - Matrix Antibiotic Management in the ICU Eleni Patrozou ******@***gmail.com Intensivist - Hygeia Hospital, Athens, Greece Infectious Diseases Division - Alpert
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationPOPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS Emmanuel Chigutsa 1, Sandra Meredith 1, Lubbe Wiesner 1, Nesri Padayatchi 2, Joe
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationTherapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients
Original Article Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients Abstract Objective: Therapeutic drug monitoring (TDM) enables individualization in the treatment
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More informationNon-commercial use only
Italian Journal of Medicine 2016; volume 10:275-281 Appropriate antibiotic therapy in critically ill patients Filippo Pieralli, Antonio Mancini, Andrea Crociani Intermediate Care Unit, Careggi University
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More informationSystematic Review of Clinical PK-PD Studies of Antibacterials. Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton
Systematic Review of Clinical PK-PD Studies of Antibacterials Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton Background It has been suggested that there are problems with current
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationCombating Antimicrobial Resistance with Extended Infusion Beta-lactams. Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationDisclosure. Objectives. Combating Antimicrobial Resistance with Extended Infusion Beta-lactams
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More informationPharmacokinetics of amoxycillin and clavulanic acid in
Br. J. clin. Pharmac. (1988), 26, 385-390 Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin B. E. DAVIES', R. BOON2, R. HORTON2,
More informationTreatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis
Journal of Antimicrobial Chemotherapy (2003) 52, 668 674 DOI: 10.1093/jac/dkg403 Advance Access publication 1 September 2003 Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationDoes Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock?
References and Literature Grading Does Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock? (9/6/2015) 1. Dellinger, R.P.,
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationGENTAMICIN DISPOSITION IN CEREBROSPINAL FLUID (CSF) AND AQUEOUS HUMOUR IN HEALTHY DOGS
Trakia Journal of Sciences, Vol. 6, Suppl. 1, pp 14-18, 2008 Copyright 2007 Trakia University Available online at: http://www.uni-sz.bg ISSN 1312-1723 GENTAMICIN DISPOSITION IN CEREBROSPINAL FLUID (CSF)
More informationFACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St.
FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St. Helier s Hospital Vancomycin and Gentamicin Audit Renal Unit St Helier Hospital
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC
ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC PREFACE INTRODUCTION The wide use and frequent misuse of antimicrobials in all countries has resulted in the emergence of drug resistance,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationExecutive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts
Executive Summary: A Point Prevalence Survey of Antimicrobial Use: Benchmarking and Patterns of Use to Support Antimicrobial Stewardship Efforts Investigational Team: Diane Brideau-Laughlin BSc(Pharm),
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationSepsis. ...striking a balance. Dr Ron Daniels.
Sepsis...striking a balance Dr Ron Daniels Fellow: NHS Improvement Faculty Chair: United Kingdom Sepsis Group, Sepsis Trust & UK SSC Sepsis as a Global Emergency Committee, Global Sepsis Alliance Midland
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationAcute Hemorrhagic Diarrhea Syndrome (AHDS) A Cause of Bloody Feces in Dogs
Acute Hemorrhagic Diarrhea Syndrome (AHDS) A Cause of Bloody Feces in Dogs No dog parent wants to clean up diarrhea. Cleaning up bloody diarrhea is even more unpleasant. Unfortunately, the development
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationThe ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs
J Antimicrob Chemother 2015; 70: 2671 2677 doi:10.1093/jac/dkv165 Advance Access publication 13 July 2015 The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs Alexis Tabah 1,2
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationPharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy Fabio Silvio Taccone, Daniel De Backer, Pierre-François Laterre, Herbert Spapen, Thierry
More informationANTIMICROBIAL DOSING GUIDE 2013
page 1 / 5 page 2 / 5 antimicrobial dosing guide 2013 pdf Stanford Hospital & Clinics Aminoglycoside Dosing Guidelines 2013 I. DETERMINING DOSE AND CREATININE CLEARANCE: 1. Use of ideal body weight (IBW)
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationPierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015
Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationPharmacokinetics of once-daily arnikacin in pediatric patients
ORIGINAL ARTICLE Pharmacokinetics of once-daily arnikacin in pediatric patients Laurence Belfayol', Philippe Talon2, atthieu Eveillardl, Patrice Alet' and rancise auvelle' 'Laboratoire de Pharmacie Clinique
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationAmikacin Inhale shows promising results in Phase II Study
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Amikacin Inhale shows promising results in Phase II Study Bayer together with Nektar Therapeutics present preliminary
More informationNUOVE IPOTESI e MODELLI di STEWARDSHIP
Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationFOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR.
Patient label DATE and TIME: 1 REVIEW BY Emergency Department SENIOR REGISTRAR (ED BLEEP 5999) +/-Leave Proforma 2 FOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR. Bloods for FBC, U+E, CRP, LFT s, Clotting
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More information